Overview

  • Product nameAnti-hHR23b antibody
    See all hHR23b primary antibodies
  • Description
    Mouse polyclonal to hHR23b
  • Tested applicationsSuitable for: WBmore details
    Unsuitable for: ICC/IF or IHC-P
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length human hHR23b protein (AAH20973)

  • Positive control
    • Human liver lysate, hHR23b transfected cell lysate, Human prostate tissue and HeLa cells

Properties

Applications

Our Abpromise guarantee covers the use of ab88503 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Predicted molecular weight: 43 kDa.
  • Application notesIs unsuitable for ICC/IF or IHC-P.
  • Target

    • FunctionMultiubiquitin chain receptor involved in modulation of proteasomal degradation. Binds to polyubiquitin chains. Proposed to be capable to bind simultaneously to the 26S proteasome and to polyubiquitinated substrates and to deliver ubiquitinated proteins to the proteasome. May play a role in endoplasmatic reticulum-associated degradation (ERAD) of misfolded glycoproteins by association with PNGase and delivering deglycosylated proteins to the proteasome.
      Involved in global genome nucleotide excision repair (GG-NER) by acting as component of the XPC complex. Cooperatively with CETN2 appears to stabilize XPC. May protect XPC from proteasomal degradation.
      The XPC complex is proposed to represent the first factor bound at the sites of DNA damage and together with other core recognition factors, XPA, RPA and the TFIIH complex, is part of the pre-incision (or initial recognition) complex. The XPC complex recognizes a wide spectrum of damaged DNA characterized by distortions of the DNA helix such as single-stranded loops, mismatched bubbles or single stranded overhangs. The orientation of XPC complex binding appears to be crucial for inducing a productive NER. XPC complex is proposed to recognize and to interact with unpaired bases on the undamaged DNA strand which is followed by recruitment of the TFIIH complex and subsequent scanning for lesions in the opposite strand in a 5'-to-3' direction by the NER machinery. Cyclobutane pyrimidine dimers (CPDs) which are formed upon UV-induced DNA damage esacpe detection by the XPC complex due to a low degree of structural perurbation. Instead they are detected by the UV-DDB complex which in turn recruits and cooperates with the XPC complex in the respective DNA repair. In vitro, the XPC:RAD23B dimer is sufficient to initiate NER; it preferentially binds to cisplatin and UV-damaged double-stranded DNA and also binds to a variety of chemically and structurally diverse DNA adducts. XPC:RAD23B contacts DNA both 5' and 3' of a cisplatin lesion with a preference for the 5' side. XPC:RAD23B induces a bend in DNA upon binding. XPC:RAD23B stimulates the activity of DNA glycosylases TDG and SMUG1.
    • Sequence similaritiesBelongs to the RAD23 family.
      Contains 1 STI1 domain.
      Contains 2 UBA domains.
      Contains 1 ubiquitin-like domain.
    • DomainThe ubiquitin-like domain mediates interaction with ATXN3.
    • Cellular localizationNucleus. Cytoplasm. The intracellular distribution is cell cycle dependent. Localized to the nucleus and the cytoplasm during G1 phase. Nuclear levels decrease during S-phase; upon entering mitosis, relocalizes in the cytoplasm without association with chromatin.
    • Information by UniProt
    • Database links
    • Alternative names
      • hHR 23b antibody
      • hHR23B antibody
      • HR 23B antibody
      • HR23B antibody
      • mHR 23B antibody
      • mHR23B antibody
      • p58 antibody
      • RAD 23B antibody
      • RAD23 (S. cerevisiae) homolog B antibody
      • RAD23 homolog B (S. cerevisiae) antibody
      • RAD23 homolog B antibody
      • RAD23 yeast homolog of B antibody
      • Rad23b antibody
      • RD23B_HUMAN antibody
      • UV excision repair protein RAD23 homolog B antibody
      • XP C repair complementing complex 58 kDa antibody
      • XP C repair complementing complex 58 kDa protein antibody
      • XP C repair complementing protein antibody
      • XP-C repair-complementing complex 58 kDa protein antibody
      • XPC repair complementing complex 58 kDa antibody
      • XPC repair complementing complex 58 kDa protein antibody
      • XPC repair complementing protein antibody
      see all

    Anti-hHR23b antibody images

    • Anti-hHR23b antibody (ab88503) at 1/500 dilution + Human liver lysate at 50 µg

      Predicted band size : 43 kDa
    • All lanes : Anti-hHR23b antibody (ab88503) at 1/500 dilution

      Lane 1 : hHR23b transfected 293T cell line
      Lane 2 : Non-transfected 293T cell line

      Lysates/proteins at 25 µg per lane.


      Predicted band size : 43 kDa

    References for Anti-hHR23b antibody (ab88503)

    This product has been referenced in:
    • Yeo W  et al. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 30:3361-7 (2012). IHC ; Human . Read more (PubMed: 22915658) »

    See 1 Publication for this product

    Product Wall

    Application Immunocytochemistry/ Immunofluorescence
    Sample Human Cell (u2os)
    Specification u2os
    Fixative Paraformaldehyde
    Username

    Abcam user community

    Verified customer

    Submitted Jan 06 2014

    Application Western blot
    Loading amount 30 µg
    Gel Running Conditions Reduced Denaturing (12%)
    Sample Human Cell lysate - whole cell (U2OS)
    Specification U2OS
    Username

    Abcam user community

    Verified customer

    Submitted Jan 06 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"